Please amend this application as follows:

In the Claims

Please amend claims 26 and add new claims 69-87 as follows:

26.(amended) A solvent vehicle, capable of solubilizing a drug with low aqueous solubility, prepared by a process comprising;

a) dissolving a drug with low aqueous solubility in a pharmaceutically acceptable dipolar aprotic solvent and/or acid;

b) further dissolving the composition of step a) in a pharmaceutically acceptable aqueous secondary solvent; and

c) removing the dipolar aprotic solvent and/or acid from the composition of step b).

~~69~~.(new) The solvent vehicle of claim 26, where the acid is acetic acid.

~~70~~.(new) The solvent vehicle of claim 26, where the dipolar aprotic solvent and/or acid is virtually eliminated from the solvent vehicle.

~~71~~.(new) The solvent vehicle of claim 26, where removing the dipolar aprotic solvent and/or acid comprises lyophilization.

~~72~~.(new) The solvent vehicle of claim 26, wherein the process further comprises reconstituting the composition of step c) in a pharmaceutically acceptable aqueous solution.

~~73~~.(new) The solvent vehicle of claim ~~72~~ 84, wherein said pharmaceutically acceptable aqueous solution comprises water, saline solution, dextrose solution, aqueous lipid emulsion, glacial acetic acid, or lipid solution.

~~74~~.(new) The solvent vehicle of claim ~~73~~ 85, wherein said pharmaceutically acceptable aqueous solution comprises water.

87 ~~75.~~(new) The solvent vehicle of claim ~~73~~ 85, wherein said pharmaceutically acceptable aqueous solution comprises saline solution.

88 ~~76.~~(new) The solvent vehicle of claim ~~73~~ 85, wherein said pharmaceutically acceptable aqueous solution comprises dextrose solution.

89 ~~77.~~(new) The solvent vehicle of claim ~~76~~ 88, wherein said dextrose solution comprises 5% to 70% dextrose in water.

90 ~~78.~~(new) The solvent vehicle of claim ~~76~~ 88, wherein said dextrose solution comprises 5% or ~~10%~~ dextrose solution.

91 ~~79.~~(new) The solvent vehicle of claim ~~73~~ 85, wherein said secondary solvent comprises a parenteral infusion fluid.

92 ~~80.~~(new) The solvent vehicle of claim 26, wherein the drug with low aqueous solubility is pimaricin.

93 ~~81.~~(new) A method for preparing a solvent vehicle comprising:

a) obtaining a pharmaceutically acceptable dipolar aprotic solvent and/or acid;

b) dissolving a drug with low aqueous solubility in said dipolar aprotic solvent and/or acid;

c) further dissolving composition of step b) in a pharmaceutically acceptable aqueous secondary solvent; and

d) removing the dipolar aprotic solvent and/or acid from the composition of step c).

94 ~~82.~~(new) The method of claim ~~81~~ 93, where the acid is acetic acid.

95 ~~83.~~(new) The method of claim ~~81~~ 93, where the dipolar aprotic solvent and/or acid is virtually eliminated from the solvent vehicle.

96 ~~84.~~(new) The method of claim ~~81~~ 93, where removing the dipolar aprotic solvent and/or acid is by lyophilization.

97 ~~85.~~(new) The method of claim ~~81~~ 93, further comprising reconstituting the composition of step d) by the addition of a pharmaceutically acceptable aqueous solvent.

98 ~~86.~~(new) The solvent vehicle of claim ~~85~~ 97, wherein said pharmaceutically acceptable aqueous solution comprises water, saline solution, dextrose solution, aqueous lipid emulsion, glacial acetic acid, or lipid solution.

99 ~~87.~~(new) The method of claim ~~81~~ 93, where the drug is pimaricin.

REMARKS

Status of Claims

Claims 26-80 were originally filed. Of these, claims 26-68 were pending following a Restriction Requirement dated October 25, 2000. In the final Office Action, dated September 24, 2001, the Examiner has withdrawn claim 49 from consideration as belonging to the Group III claims of said Restriction Requirement. In this amendment, claim 26 has been amended and claims 69-87 have been added. Thus, claims 26-48, 50-68 and new claims 69-87 are currently pending in the case.

Support for Claims

Support for amended claim 26 and the new claims 69-87 are found in the specification as originally filed in the case. In particular, support can be found as follows:

In general, support for claims 26, 69-71, 72-79, and 80 can be found, at least, at page 5, lines 9-21, at page 11, lines 2-6 and lines 21-24; page 13, lines 25-28; page 18, lines 22-29; page